HealthLynked CFO granted 35,000 stock options

HealthLynked Corp reported that Chief Financial Officer O'Leary George received a grant of 35,000 options to purchase common stock at an exercise price of $3.50 per share.

Accepted by SEC EDGAR 07/24/2026 - 04:09 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

HealthLynked Corp reported that Chief Financial Officer O'Leary George received a grant of 35,000 options to purchase common stock at an exercise price of $3.50 per share. These options vest in full upon successful approval for listing on the Nasdaq Capital Market while he serves as Interim CFO and expire on July 22, 2036. Following this award, he holds 37,612 derivative securities, including the new options and 2,612 warrants exercisable at $6.70 per share.

Insider Trade Summary

Grant/Award: 35,000 shares

Grant/Award 1 txn

Insider O'Leary George

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Options to purchase common stock F1, F2	35,000	$0.00	$0.00

Holdings After Transaction: Options to purchase common stock — 37,612 contracts (Direct)

Holdings Before and After: Options to purchase common stock, 2,612 to 37,612 contracts (Direct)

Footnotes (2)

1. F1. Options vest in full upon the Issuer's successful approval for listing on the Nasdaq Capital Market while filer is actively serving as Interim Chief Financial Officer of the Issuer.
2. F2. Includes options being reported hereunder plus 2,612 warrants with an exercise price of $6.70.

Key Figures

Options granted: 35,000 options Option exercise price: $3.50 per share Option expiration date: July 22, 2036 +3 more

6 metrics

Options granted 35,000 options Grant of options to purchase common stock to CFO on July 22, 2026

Option exercise price $3.50 per share Exercise price for the 35,000 options granted to the CFO

Option expiration date July 22, 2036 Expiration date of the 35,000 options awarded

Derivative securities after grant 37,612 Total derivative securities held after the award, including options and warrants

Warrants held 2,612 warrants Warrants included in post-award holdings, separate from the new options

Warrant exercise price $6.70 per share Exercise price for the 2,612 warrants held by the CFO

Key Terms

Nasdaq Capital Market, Interim Chief Financial Officer, exercise price, warrants

4 terms

Nasdaq Capital Market regulatory

"Options vest in full upon the Issuer's successful approval for listing on the Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

Interim Chief Financial Officer financial

"while filer is actively serving as Interim Chief Financial Officer of the Issuer"

An interim chief financial officer is a temporary leader responsible for managing a company's financial activities, such as budgeting, financial planning, and reporting, during a transitional period. Think of it as filling in for a key manager until a permanent replacement is found. For investors, this role is important because it ensures financial stability and clear guidance during times of change or uncertainty.

exercise price financial

"2,612 warrants with an exercise price of $6.70"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

warrants financial

"plus 2,612 warrants with an exercise price of $6.70"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did HealthLynked (HLYK) disclose in this Form 4?

HealthLynked (HLYK) disclosed that CFO O'Leary George received a grant of 35,000 stock options to purchase common shares at an exercise price of $3.50 per share. The award is reported as a derivative security acquisition with no cash purchase price.

What are the vesting conditions for the new HLYK CFO stock options?

The 35,000 options vest in full only upon the company’s successful approval for listing on the Nasdaq Capital Market, while O'Leary George is actively serving as Interim Chief Financial Officer. If these conditions are not met, the options would not vest under this provision.

What is the exercise price and expiration date of the HLYK options grant?

The granted options carry an exercise price of $3.50 per share and an expiration date of July 22, 2036. This means the CFO may purchase common stock at $3.50 per share any time before that expiration, subject to the vesting condition being satisfied.

How many derivative securities does the HLYK CFO hold after this grant?

After the grant, O'Leary George holds 37,612 derivative securities in total. This figure includes the newly granted 35,000 options plus 2,612 warrants, as specified in the filing’s footnote clarifying the post-transaction amount.

Does the HLYK CFO hold any warrants in addition to the new options?

Yes. The post-transaction total of 37,612 derivative securities includes 2,612 warrants with an exercise price of $6.70 per share. These warrants are held alongside the newly granted 35,000 options to purchase HealthLynked common stock.

Was the HealthLynked (HLYK) CFO options grant reported as a purchase or an award?

The transaction is coded as an award (code A), described as a grant or other acquisition of derivative securities. It reflects compensation in the form of stock options, not an open-market share purchase or sale by the CFO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Leary George

(Last) (First) (Middle)

1265 CREEKSIDE PKWY, SUITE 200

(Street)

NAPLES FLORIDA 34108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HealthLynked Corp [ HLYK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase common stock	$3.5	07/22/2026		A		35,000		(1)	07/22/2036	Common stock	35,000	$0.00	37,612(2)	D

Explanation of Responses:

1. Options vest in full upon the Issuer's successful approval for listing on the Nasdaq Capital Market while filer is actively serving as Interim Chief Financial Officer of the Issuer.

2. Includes options being reported hereunder plus 2,612 warrants with an exercise price of $6.70.

	/s/ George O'Leary	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)